anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Quality-adjusted life-year (QALY) is a dominant measurement of health gain in economic evaluations for pricing drugs. However, end-of-life (EoL) patients' preference for QALY gains in life expectancy (LE) and quality of life (QoL) during different disease stages remains unknown and is seldom involved in decision-making. This study aims to measure preferences and willingness-to-pay (WTP) towards different types of QALY gain among EoL cancer patients.
METHODS: We attributed QALY gain to four types, gain in LE and QoL, respectively, and during both progression-free survival (PFS) and post-progression survival (PPS). A discrete choice experiment including five attributes (the four QALY attributes and one cost attribute) with three levels each was developed and conducted with 85 Chinese advanced non-small cell lung cancer patients in 2022. All levels were set with QALY gain/cost synthesised from research on anti-lung cancer drugs recently listed by Chinese National Healthcare Security Administration. Each respondent answered six choice tasks in a face-to-face interview. The data were analysed using mixed logit models.
RESULTS: Patients valued LE-related QALY gain in PFS most, with a relative importance of 81.8% and a WTP of $43,160 [95% CI 26,751 ~ 59,569] per QALY gain. Respondents consistently preferred LE-related to QoL-related QALY gain regardless of disease stage. Patients with higher income or lower education levels tended to pay more for QoL-related QALY gain.
CONCLUSION: Our findings suggest a prioritised resource allocation to EoL-prolonging health technologies. Given the small sample size and large individual heterogeneity, a full-scale study is needed to provide more robust results.
FIELD: organic chemistry, steroids, pharmacy. SUBSTANCE: invention relates to the homogeneous steroid-containing substance for preparing pharmaceutical preparations with content from 0.01% to 1% of steroid weight. Substance is prepared by evaporation of disperser containing steroidal active component from suspension diluted with a pharmaceutically usual accessory substance by mist spraying. Mean drop diameter of mist is larger as compared with mean diameter of accessory substance particles. Maximal granularity index of dried particles of steroid-containing substance increases less by 30% as compared with granularity index of accessory substance. The proposed substance shows homogeneity and stability against stratification and steroidal active component forms small-dispersed matter and uniformly bound with accessory substance. Choice of technological conditions for spraying process carrying out provides to bind an active component with accessory substance uniformly and almost completely. EFFECT: improved method of preparing, improved properties of substance. 6 cl, 3 ex
INTRODUCTION: Protracted febrile myalgia syndrome (PFMS) is a rare manifestation of familial Mediterranean fever (FMF), characterized by myalgia, fever and elevated inflammatory markers lasting several weeks. As the hallmark of FMF are short episodes of disease symptoms, the long duration of PFMS may lead to a delayed diagnosis and treatment.
OBJECTIVES: 1. To perform a review of literature and rheumatology textbooks focused on clinical features and treatment of PFMS in children. 2. To present our own case.
METHODS: All articles in Pub Med generated using the keywords "protracted febrile myalgia" and information on PFMS in seven rheumatology textbooks were collected. The systematic review was supplemented with our own case presentation.
RESULTS: In total, 18 articles with 78 pediatric patients (including our own) were retrieved. More than half of the patients presented with PFMS as the first manifestation of FMF. All complained of myalgia, 65% of abdominal pain and 26% had a rash. Corticosteroids (CS) were effective in 77%. In all CS-refractory cases, anakinra was shown efficient. MRI was used in 5 patients and showed myositis in all of them. The scrutiny of seven rheumatology textbooks showed that PFMS presenting with myalgia was mentioned in six. Possible accompanying symptoms were described only once, the long duration of symptoms twice, the efficacy of corticosteroids three times and anakinra only once. The presented 6 year old patient manifested with fever, myalgia, abdominal pain and petechial rash lasting 6 weeks. She had undergone multiple diagnostic procedures before her parents mentioned a positive family history for FMF. The subsequent genetic testing confirmed a homozygosity for M694V pathogenic variant in the MEFV gene.
CONCLUSION: The long duration of PFMS may be misleading to clinicians especially if PFMS occurs at manifestation of FMF. The fact that more than half of the reported patients experienced PFMS as the presenting symptom of FMF is one of the key findings of our study. Our case presentation demonstrates the importance of genetic testing early in suspected autoinflammatory diseases. Furthermore, MRI may be an important diagnostic tool showing myositis in PFMS.
The invention discloses application of diterpenoid compounds in preparing medicaments for treating cardiovascular diseases, and discloses novel activity data of 2 known compounds and application thereof in remarkably inhibiting oxidative stress injury activity of SH-SY5Y cells. Wherein the damage survival rates of the compounds 1 and 2 to SH-SY5Y cells are 84.8% and 87.4%, respectively. Compounds 1 and 2 significantly inhibited Bax protein production, thereby inhibiting SH-SY5Y apoptosis. All 2 compounds have application prospect for treating cardiovascular diseases. The compound is separated from an egg nest fungus fermentation product, and the strain is purchased from China general microbiological culture collection center (CGMCC), and the number is as follows: CGMCC 5.1117. Meanwhile, the strain is stored in a natural product laboratory of a Shallo college and is No. CA 201510823.
Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.
This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be directly on the trigger point. The intervention will be administered one time.
The present invention provides a bioreactor for large-mammal lung tissue. The bioreactor is capable of hydraulic driven negative-pressure and positive-pressure perfusion and ventilation. Perfusion and ventilation is delivered at physiological rates and is easily controllable. In one embodiment, the bioreactor comprises a support scaffold to support the size of a large-mammal lung tissue. In another embodiment, the bioreactor comprises a pleural sack that provides a small isolated fluid chamber which surrounds an engineered lung, thereby minimizing the amount of culture media needed. The present invention also provides an in vitro model for examining the function of a test agent and compositions and methods for alleviating a lung defect in a large-mammal.
This trial aims to assess the effects of intragastric administration of quinine, combined with L-isoleucine, on postprandial blood glucose, gastric emptying, gut and gluco-regulatory hormones, as well as appetite perceptions in response to a mixed-nutrient drink.

Each participant will be studied on 4 occasions, separated by 3-7 days. Participants will receive, in randomized, double-blind fashion, an intragastric bolus of (i) 300 mg quinine, (ii) 5 g L-isoleucine, (iii) combination of (i)+(ii), or (iv) control. Due to the low water solubility, L- isoleucine will be provided as a suspension using 5 ml of 'the suspending agent' Ora-Plus (manufactured by Perrigo, Minneapolis). Visits will be carried out at the Clinical Research Facility, Adelaide Medical School, University of Adelaide, by staff and students trained in the required clinical research techniques.

Participants will consume a standardized dinner meal (400g McCain's beef lasagne) the night before each study visit by no later than 7 pm. After fasting for 13.5 hours overnight and refraining from alcohol and exercise for 24 hours, participants will arrive at the Clinical Research Facility by 8:30 am. Upon arrival, participants will be intubated with a nasogastric, custom-built soft silicon feeding tube (outer diameter: 4mm; Dentsleeve, Mississauga, Ontario, Canada) that will be inserted through an anaesthetized nostril and placed in the stomach. An intravenous cannula will be placed into a right forearm vein for regular blood sampling. At t = -60 min, a venous baseline blood sample (6 ml) will be collected and the participant will complete a visual analogue scale questionnaire (VAS) to assess appetite-related perceptions (fullness, hunger, desire to eat, prospective food consumption) and GI symptoms (nausea and bloating). Immediately thereafter, the participant will receive a 10- ml intragastric bolus of either 300 mg quinine-hydrochloride (Q-HCl) or water (control), and 30 min later, at t -30 min, an intragastric bolus of L-isoleucine (100 ml suspension consisting of 5 g L- isoleucine, 5 ml Ora-Plus and 90 ml 0.9% saline) or control (5 ml Ora-Plus and 95 ml saline) over 1 min after which time the catheter will be removed immediately. At t = -1 min, the participant will consume, within 1 min, a mixed-nutrient drink (Nestle, 500 kcal, 350 ml, 56 g carbohydrates) labelled with 100 mg of 1-13C-acetate for measurement of gastric emptying by breath sampling. Breath samples will be collected in sealed breath bags at baseline (prior to quinine administration) and at regular intervals between t = 0-180 min, for subsequent analysis of 13CO2 concentration in exhaled breath. Blood samples for the measurement of glucose and plasma concentrations of hormones will be taken regularly (12 sampling time points in total), and participant complete VAS questionnaires. At I = 180 min, after final blood and breath samples and VAS measurements, the intravenous cannula will be removed and the participant will be served a light lunch, after which they will be allowed to leave the laboratory.
A method of obtaining and applying the materials required for autoantigen immunological recognition after birth to treat rejection and immune system diseases. Especially, the method of making and obtaining early immunological recognition hemopoietic stem cells and/or late immunological recognition hemopoietic stem cells required for autoantigen immunological recognition, and obtaining the immune relating tissues and organs of the autoantigen immunological recognition period, comprising: the autoantigen immunological recognition relating cells and factors etc. in the thymus and marrow. The method for treating rejection and immune system diseases to carry on the autoantigen immunological recognition to each tissue, organ and graft antigen with autoantigen variations. The present method could not only treat multiple diseases conditions related to the immune disorders and the rejection after organ graft, but also treat varieties of diseases for different organs of the receptors. The present invention could be applied not only to human beings, but also to animals.
A secure safety container is made up with a base and a cover that can be locked together by an electric operated lock carried by the container. The top and base of the container together form a secure space within the container sized and configured to receive an article or articles. Also carried by the container are a CPU with a touch data entry screen, a rechargeable battery, date entry and infra red data entry ports, a tracking transponder and a thermister to provide humidity and temperature inputs to the CPU. After entry into the CPU of insert data relative to the article or articles to be secured within the secure space the electric lock may be activated to secure the container cover to its base. Upon entry of corresponding retrieve data into the CPU and the CPU determining that there is a “match” between the insert data and retrieve data the electric lock is operated by the CPU to permit access to the secure space within the container and retrieval of the article or articles therein. Such article or articles may be units of blood or uman organs to be “matched” to the patient to receive same or crime scene evidence for which a “chain of custody” is required or similar articles.
OBJECTIVE: Lumbosacral hydatid disease (LHD), a rare skeletal parasitic disease that involves the lumbosacral region. In this study, we summarized the diagnostic and therapeutic procedures for patients with LHD to provide insights into managing this rare disease.
METHODS: Between 2000 and 2023, 16 patients diagnosed with LHD were retrospectively analyzed. Each patient's medical records and follow-up details, were carefully assessed. The average follow-up period was 11.25 ± 6.41 years, providing valuable insights into treatment durability and effectiveness.
RESULTS: The diagnosis was confirmed via imaging, serological tests, and pathological examination. The clinical symptoms included lumbago with lower limb numbness (25 %) and urinary and fecal incontinence (25 %). All patients underwent surgery, with an average of 2.6 surgeries per patient. Thirteen (81.25 %) patients experienced recurrence postoperatively.
CONCLUSION: LHD is a severe and complex skeletal parasitic disease with significant diagnostic and therapeutic challenges. Effective management requires a comprehensive strategy involving surgery and additional therapies.
Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with EPRONTIA use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures.

The majority of the reports have been in pediatric patients. Patients (especially pediatric patients) treated with EPRONTIA should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Caution should be used when EPRONTIA is given with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.
Necrosis of the femoral head is the main complication in femoral neck fracture patients with triangle cannulated screw fixation. Instant postoperative fixation instability is a main reason for the higher risk of femoral head necrosis. Biomechanical studies have shown that cross screw fixation can effectively optimize fixation stability in patients with proximal humerus fractures and pedicle screw fixation, but whether this method can also effectively optimize the fixation stability of femoral neck fractures and reduce the corresponding risk of femoral head necrosis has yet to be identified. In this study, a retrospective review of imaging data in femoral neck fracture patients was performed. The cross angle between the femoral neck and the caudal cannulated screw was reported; if the angle between the screw and the transverse plane increased, it was recorded as positive; otherwise, it was recorded as negative. Angle values and their corresponding absolute values were compared in patients with and without femoral head necrosis. Regression analysis identified potential risk factors for femoral head necrosis. Moreover, the biomechanical effect of the screw-femoral neck angle on fixation stability was also verified by numerical mechanical simulations. Clinical review presented significantly larger positive angle values in patients with femoral head necrosis, which was also proven to be an independent risk factor for this complication. Moreover, fixation stability progressively deteriorated with increasing angle between the caudal screw and the transverse plane. Therefore, increasing the angle between the caudal screw and the transverse plane may aggravate the risk of femoral head necrosis by deteriorating the fixation stability in patients with femoral neck fracture.
Radial Extracorporeal Shock Wave Therapy will be given for 3 weeks, 1 days in a week. Moreover 10-12 minutes cold pack will apply for every session.
PURPOSE: To obtain an oral administration preparation containing the solid solution of irsogladine maleate with an inactive carrier, having a strong antiulcer action and capable of being rapidly dissolved at a specific speed. CONSTITUTION: This preparation contains a solid solution obtained by compounding (A) 1 pt. of irsogladine maleate with (B) a carrier comprising a medicinally inactive polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone (e.g. crospovidone), and a cellulose derivative (e.g. crystalline cellulose, hydroxypropyl cellulose, ethyl cellulose) preferably in an amount of 0.1-200 pts. (especially approximately 1-30 pts.). The preparation is shaped into tablets, granules, fine granules, capsules, etc. The solid solution is formed by a dry method or a wet method. The former method comprises grinding the solid solution with a ball mill, etc., at room temperature for approximately 2-4hrs.  The latter method comprises dissolving the components A and B in an organic solvent and/or water, and subsequently distilling off the solvents, or preliminarily dissolving the component A in the organic solvent and/or water and subsequently allowing the component B to adsorb the solution.
FIELD: pharmaceutical preparations. SUBSTANCE: method involves dissolving of solid substance in organic solvent-carrier and its contacting with superfluid medium under supercritical conditions. Contacting is carried out by injection of solution in antisolvent. Tetrahydrofuran, carbon dioxide and triancinolone acetonide were used as a solvent-carrier, antisolvent and solid substance, respectively. Injection solution is added to the reactor continuously or at the regular intervals. EFFECT: improved method of pharmaceutical substance preparing. 7 cl, 1 dwg, 2 tbl
Naloxone hydrochloride injection, USP, an opioid antagonist, is a synthetic congener of oxymorphone. In structure it differs from oxymorphone in that the methyl group on the nitrogen atom is replaced by an allyl group.

NALOXONE HYDROCHLORIDE

Naloxone hydrochloride occurs as a white to slightly off-white powder, and is soluble in water, in dilute acids, and in strong alkali; slightly soluble in alcohol; practically insoluble in ether and in chloroform.

Naloxone hydrochloride injection, USP is available as a sterile, clear colorless solution for intravenous, intramuscular and subcutaneous administration in 1 mg/mL concentration. The pH is adjusted to 3.5 ± 0.5 with hydrochloric acid. Each mL also contains 8.35 mg of sodium chloride. Naloxone hydrochloride injection is preservative-free.
PROBLEM TO BE SOLVED: To obtain the subject prevention and/or curing agent having excellent effect for preventive and/or curing enteric disease, especially an enteral hemorrhage due to inflammatory enteric disease by including glycosaminoglycan sulfate. SOLUTION: This agent contains glycosaminoglycan sulfate, preferably chondroitin sulfate having 10,0000-40,000 molecular weight or its salt (e.g. sodium chondroitin sulfate) as an active component. The glycosaminoglycan sulfate, e.g. chondroitin sulfate in a shape of proteoglycan is obtained by e.g. using a gristle of an aquatic animal such as a shark, a mammal such as cattle or swine or birds as a raw material, extracting by a known method such as a neutral salt method, removing fat.solid component, etc., and drying. Preferably, an administration amount of the agent is daily 20-500 mg as a weight of glycosaminoglycan sulfate of the active component per 1 kg of a body weight. Preferably, 0.1-90 wt.% of glycosaminoglycan is contained in the objective formulation.
Group 1 will receive 1hr of electrical stimulation while lying down followed by 15 min of overground training. Electrical stimulation will be applied through leads and self-adhesive electrodes over muscles of both legs. Two electrodes will be used for each muscle. Electrical stimulation will be induced by using the EMPI, Inc., St. Paul, MN \[Respond Select Neuromuscular Stimulation\]. There will be 60 sessions/3x week for 20 weeks.
This invention is of particular use to patients with Diabetes Mellitus. It uses alkyl analogs of the methyl pyruvate (MP) family to provide energy and improve insulin and glucose homeostasis via accelerated intracellular delivery of protons, pyruvate and ATP from each MP. The energy upregulates cellular cross talk and networking resulting in a surge of ATP enabling NADH (via glycolysis) that enables pancreatic islet cells to obtain increased ATP allowing increased insulin manufacture. This process improves cellular respiration, expedites protein, lipid and hormone manufacture. The increased energy also enables telomeres and delays Hayflick limit. Instead of cellular repair, silence, or apoptosis, energy is allocated for cell/organ function. This invention curbs inflammation and ROS by idealizing cellular respiration and diminishing hyperglycemia. In turn a reduction of advanced glycation end products (AGEs), lessened target RNA and nucleic acid toxins, i.e., diminished HbA1c occurs. By decreased drain of cellular energy, genomic function improves.
Participants in this arm will receive transcranial Direct Current Stimulation (tDCS) targeting the primary motor cortex (M1). The tDCS will be administered at an intensity of 2 mA for 20 minutes. This arm aims to evaluate the effects of M1 stimulation on performance during a maximal effort "No Jump Burpee" exercise.
Immunotherapy improves clinical outcome of patients with advanced stage or metastatic esophageal squamous cell carcinoma (ESCC). In addition, superior effect of immunotherapy for esophageal squamous cell carcinoma was also reported recently. While, clinical application of ctDNA, PD-L1 and CD8 T cell monitoring in neoadjuvant immunotherapy for patients with esophageal squamous cell carcinoma is largely unknown. This trial will evaluate firstly the efficacy and the safety of Camrelizumab plus chemotherapy （albumin-bound paclitaxel plus cisplatin）as neoadjuvant approach. The evaluation indicators include pathological complete response rate (pCR) and objective imaging response rate after neoadjuvant therapy (ORR). ), 2-year progression-free survival (2y-PFS), postoperative progression-free survival (PFS), and overall survival (OS) after treatment. Objective response rate (ORR) based upon immune-Response Evaluation Criteria in Solid Tumors Version (RECIST v1.1). Major pathological response assessed by post-operational pathological review ctDNA efficacy will also be evaluated along with clinical management. Monitoring tumor burden, clonality as well as tumor heterogeneity evaluation will be correlated to radiological assessment and pathological findings.
Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.